Hikma Pharmaceutical reported 600M in Cost of Sales for its first fiscal semester of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
AstraZeneca AZN:LN 2193M 273M
Bayer BAYN:GR € 4546M 152M
Fresenius FRE:GR € 6628M 102M
GlaxoSmithKline GSK:LN 2519M 108M
GRIFOLS GRF:SM € 771.1M 119.7M
H. Lundbeck A/S LUN:DC 851M 513M
Hikma Pharmaceutical HIK:LN 600M 2M
Lonza Group LONN:SW 1.5B 690M
Merck MRK:GR € 1813M 92M
Orion ORNBV:FH 99.6M 15.1M
Recordati REC:IM 101.87M 2.2M